MONTE ROSA THERAPEUTICS INC. - COMMON STOCK

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

03 июл 2025 11:15:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

10 июн 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

28 май 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

08 май 2025 04:00:01 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

28 апр 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

20 мар 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

11 мар 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

24 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

10 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

13 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

11 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

11 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

05 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

26 ноя 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

13 ноя 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

07 ноя 2024 04:00:01 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

28 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

23 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

28 авг 2024 04:00:00 Источник Nasdaq GlobeNewswire